Cargando…
Diagnostic and prognostic role of HE4 expression in multiple carcinomas: A protocol for systematic review and meta-analysis
BACKGROUND: Human epididymis protein 4 (HE4) protein has garnered a great degree of interest as a complementary biomarker to carbohydrate antigen 125 (CA125), or even as an independent biomarker for monitoring, diagnosis, and prognostication of ovarian cancer. Its use is currently limited to ovarian...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6641664/ https://www.ncbi.nlm.nih.gov/pubmed/31305389 http://dx.doi.org/10.1097/MD.0000000000015336 |
_version_ | 1783436825678839808 |
---|---|
author | Kumarasamy, Chellan Madhav, Madurantakam Royam Sabarimurugan, Shanthi Lakhotiya, Kartik Pandey, Venkatesh Priyadharshini, T Baxi, Siddhratha Gothandam, KM Jayaraj, Rama |
author_facet | Kumarasamy, Chellan Madhav, Madurantakam Royam Sabarimurugan, Shanthi Lakhotiya, Kartik Pandey, Venkatesh Priyadharshini, T Baxi, Siddhratha Gothandam, KM Jayaraj, Rama |
author_sort | Kumarasamy, Chellan |
collection | PubMed |
description | BACKGROUND: Human epididymis protein 4 (HE4) protein has garnered a great degree of interest as a complementary biomarker to carbohydrate antigen 125 (CA125), or even as an independent biomarker for monitoring, diagnosis, and prognostication of ovarian cancer. Its use is currently limited to ovarian cancer. Recent studies have suggested that it could also be used in other types of cancers. METHODS: The Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines was used to design this meta-analysis protocol. The final study will also be conducted under the PRISMA guidelines for systematic reviews and meta-analyses. The core bibliographic database search will be carried out by 2 reviewers working individually, with each conducting an initial screening based on titles and abstracts. The shortlisted articles will be selected for review and statistical analysis based on predefined inclusion and exclusion criteria. Study characteristics, relevant clinicopathological characteristics and statistical data required for meta-analysis (hazard ratios [HRs] and 95% confidence interval [CIs) will be extracted and compiled into a MS Excel datasheet. Meta-analysis will be performed, using a random-effects model, and the results (pooled HR and 95% CI) will be presented in the form of a forest plot. Publication bias will also be assessed by use of Egger bias indicator test and funnel plot symmetry. If data are insufficient, a narrative line of review will be pursued. DISCUSSION: HE4 protein has been shown to have great potential for clinical use as a diagnostic and prognostic marker in epithelial ovarian cancer (EOC). However, HE4 is not only limited to expression in ovarian cancer, but is also overexpressed in lung and endometrial cancers. The effectiveness of HE4 as a biomarker in cancers (other than EOC) has not yet been studied in the form of a comprehensive systematic review and meta-analysis. The results of this study should allow for expanded use of HE4 as a multiutility biomarker in multiple cancer types, thereby, elevating HE4's value as a cancer biomarker. PROSPERO REGISTRATION: CRD42019120326. |
format | Online Article Text |
id | pubmed-6641664 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-66416642019-08-15 Diagnostic and prognostic role of HE4 expression in multiple carcinomas: A protocol for systematic review and meta-analysis Kumarasamy, Chellan Madhav, Madurantakam Royam Sabarimurugan, Shanthi Lakhotiya, Kartik Pandey, Venkatesh Priyadharshini, T Baxi, Siddhratha Gothandam, KM Jayaraj, Rama Medicine (Baltimore) Research Article BACKGROUND: Human epididymis protein 4 (HE4) protein has garnered a great degree of interest as a complementary biomarker to carbohydrate antigen 125 (CA125), or even as an independent biomarker for monitoring, diagnosis, and prognostication of ovarian cancer. Its use is currently limited to ovarian cancer. Recent studies have suggested that it could also be used in other types of cancers. METHODS: The Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines was used to design this meta-analysis protocol. The final study will also be conducted under the PRISMA guidelines for systematic reviews and meta-analyses. The core bibliographic database search will be carried out by 2 reviewers working individually, with each conducting an initial screening based on titles and abstracts. The shortlisted articles will be selected for review and statistical analysis based on predefined inclusion and exclusion criteria. Study characteristics, relevant clinicopathological characteristics and statistical data required for meta-analysis (hazard ratios [HRs] and 95% confidence interval [CIs) will be extracted and compiled into a MS Excel datasheet. Meta-analysis will be performed, using a random-effects model, and the results (pooled HR and 95% CI) will be presented in the form of a forest plot. Publication bias will also be assessed by use of Egger bias indicator test and funnel plot symmetry. If data are insufficient, a narrative line of review will be pursued. DISCUSSION: HE4 protein has been shown to have great potential for clinical use as a diagnostic and prognostic marker in epithelial ovarian cancer (EOC). However, HE4 is not only limited to expression in ovarian cancer, but is also overexpressed in lung and endometrial cancers. The effectiveness of HE4 as a biomarker in cancers (other than EOC) has not yet been studied in the form of a comprehensive systematic review and meta-analysis. The results of this study should allow for expanded use of HE4 as a multiutility biomarker in multiple cancer types, thereby, elevating HE4's value as a cancer biomarker. PROSPERO REGISTRATION: CRD42019120326. Wolters Kluwer Health 2019-07-12 /pmc/articles/PMC6641664/ /pubmed/31305389 http://dx.doi.org/10.1097/MD.0000000000015336 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | Research Article Kumarasamy, Chellan Madhav, Madurantakam Royam Sabarimurugan, Shanthi Lakhotiya, Kartik Pandey, Venkatesh Priyadharshini, T Baxi, Siddhratha Gothandam, KM Jayaraj, Rama Diagnostic and prognostic role of HE4 expression in multiple carcinomas: A protocol for systematic review and meta-analysis |
title | Diagnostic and prognostic role of HE4 expression in multiple carcinomas: A protocol for systematic review and meta-analysis |
title_full | Diagnostic and prognostic role of HE4 expression in multiple carcinomas: A protocol for systematic review and meta-analysis |
title_fullStr | Diagnostic and prognostic role of HE4 expression in multiple carcinomas: A protocol for systematic review and meta-analysis |
title_full_unstemmed | Diagnostic and prognostic role of HE4 expression in multiple carcinomas: A protocol for systematic review and meta-analysis |
title_short | Diagnostic and prognostic role of HE4 expression in multiple carcinomas: A protocol for systematic review and meta-analysis |
title_sort | diagnostic and prognostic role of he4 expression in multiple carcinomas: a protocol for systematic review and meta-analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6641664/ https://www.ncbi.nlm.nih.gov/pubmed/31305389 http://dx.doi.org/10.1097/MD.0000000000015336 |
work_keys_str_mv | AT kumarasamychellan diagnosticandprognosticroleofhe4expressioninmultiplecarcinomasaprotocolforsystematicreviewandmetaanalysis AT madhavmadurantakamroyam diagnosticandprognosticroleofhe4expressioninmultiplecarcinomasaprotocolforsystematicreviewandmetaanalysis AT sabarimuruganshanthi diagnosticandprognosticroleofhe4expressioninmultiplecarcinomasaprotocolforsystematicreviewandmetaanalysis AT lakhotiyakartik diagnosticandprognosticroleofhe4expressioninmultiplecarcinomasaprotocolforsystematicreviewandmetaanalysis AT pandeyvenkatesh diagnosticandprognosticroleofhe4expressioninmultiplecarcinomasaprotocolforsystematicreviewandmetaanalysis AT priyadharshinit diagnosticandprognosticroleofhe4expressioninmultiplecarcinomasaprotocolforsystematicreviewandmetaanalysis AT baxisiddhratha diagnosticandprognosticroleofhe4expressioninmultiplecarcinomasaprotocolforsystematicreviewandmetaanalysis AT gothandamkm diagnosticandprognosticroleofhe4expressioninmultiplecarcinomasaprotocolforsystematicreviewandmetaanalysis AT jayarajrama diagnosticandprognosticroleofhe4expressioninmultiplecarcinomasaprotocolforsystematicreviewandmetaanalysis |